Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $300000.0.

  • Ernexa Therapeutics' Change in Accured Expenses rose 13792.67% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$738000.0, marking a year-over-year increase of 7721.52%. This contributed to the annual value of $183000.0 for FY2024, which is 10631.47% up from last year.
  • According to the latest figures from Q3 2025, Ernexa Therapeutics' Change in Accured Expenses is $300000.0, which was up 13792.67% from -$410000.0 recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' Change in Accured Expenses peaked at $1.8 million during Q2 2022, and registered a low of -$4.0 million during Q4 2023.
  • In the last 5 years, Ernexa Therapeutics' Change in Accured Expenses had a median value of $123500.0 in 2025 and averaged -$100625.0.
  • Over the last 5 years, Ernexa Therapeutics' Change in Accured Expenses had its largest YoY gain of 26898.8% in 2023, and its largest YoY loss of 70744.68% in 2023.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Change in Accured Expenses stood at -$766000.0 in 2021, then soared by 185.9% to $658000.0 in 2022, then tumbled by 707.45% to -$4.0 million in 2023, then skyrocketed by 85.61% to -$575000.0 in 2024, then soared by 152.17% to $300000.0 in 2025.
  • Its Change in Accured Expenses was $300000.0 in Q3 2025, compared to -$410000.0 in Q2 2025 and -$53000.0 in Q1 2025.